Memantine Hydrochloride Tablet, Film Coated
Product Images NDC 68180-230

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 68180-230). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lupin Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (00171da8 B6f1 4f4d Afd9 04f7ea35dd04 01)

Chemical structure of Memantine hydrochloride showing the molecular arrangement including amine (NH2) and methyl (CH3) groups attached to a polycyclic framework.*

FDA Label Image

Figure 1 (00171da8 B6f1 4f4d Afd9 04f7ea35dd04 02)

A line graph depicting mean change from baseline in ADCS-ADL scores over 28 weeks of treatment for Memantine versus Placebo groups. The x-axis represents weeks of treatment (0, 4, 12, 28), and the y-axis shows mean change with SEM. The Memantine group shows less decline compared to Placebo, which exhibits greater clinical decline over time.*

FDA Label Image

Figure 2 (00171da8 B6f1 4f4d Afd9 04f7ea35dd04 03)

A cumulative percentage line graph comparing patients treated with Memantine versus Placebo. The x-axis shows ADCS-ADL change from baseline values, with negative scores indicating improvement. The y-axis displays the cumulative percentage of patients, ranging from 0 to 100. Memantine shows higher cumulative percentages across the improvement scale compared to Placebo, according to the legend.*

FDA Label Image

Figure 3 (00171da8 B6f1 4f4d Afd9 04f7ea35dd04 04)

A line graph showing mean change from baseline in SIB score over 28 weeks of treatment comparing placebo and memantine. The y-axis represents mean ± SEM change, with zero indicating baseline. The placebo group shows a steady decline in score, nearing clinical decline by week 28. The memantine group remains near baseline initially and shows less decline by week 28, suggesting clinical improvement relative to placebo.*

FDA Label Image

Figure 4 (00171da8 B6f1 4f4d Afd9 04f7ea35dd04 05)

A line graph showing cumulative percentage of patients (y-axis) over an unspecified variable (x-axis). Two data series are plotted: one labeled Placebo represented by black squares, and the other labeled Memantine represented by open circles. The Memantine group shows a higher cumulative percentage of patients across the measured range compared to the Placebo group.*

FDA Label Image

Figure 5 (00171da8 B6f1 4f4d Afd9 04f7ea35dd04 06)

A line graph showing the mean change from baseline in ADCS-ADL score over 24 weeks of treatment, comparing Placebo/Donepezil and Memantine/Donepezil groups. The x-axis represents weeks of treatment, and the y-axis shows the mean change with clinical improvement and decline marked. Data points include error bars.*

FDA Label Image

Figure 6 (00171da8 B6f1 4f4d Afd9 04f7ea35dd04 07)

A cumulative percentage of patients line graph comparing ADCS-ADL change from baseline between two treatments: Placebo/Donepezil and Memantine/Donepezil. The x-axis represents ADCS-ADL change from baseline, ranging from positive to negative values. The y-axis shows the cumulative percentage of patients, ranging from 0% to 100%. Memantine/Donepezil shows a higher cumulative percentage at greater negative ADCS-ADL change values compared to Placebo/Donepezil.*

FDA Label Image

Figure 7 (00171da8 B6f1 4f4d Afd9 04f7ea35dd04 08)

A line graph showing mean change from baseline in SIB Score over 24 weeks of treatment comparing Memantine/Donepezil versus Placebo/Donepezil. The x-axis represents weeks of treatment, and the y-axis represents mean change (± SEM). Memantine/Donepezil shows improvement with scores peaking around 12 weeks, while Placebo/Donepezil shows a decline over time. Error bars indicate variability in data.*

FDA Label Image

Figure 8 (00171da8 B6f1 4f4d Afd9 04f7ea35dd04 09)

A cumulative percentage graph showing patient responses comparing Memantine/Donepezil and Placebo/Donepezil groups. The x-axis represents SIB (Severe Impairment Battery) change from baseline, ranging from 20 to -30, and the y-axis shows cumulative percentage of patients from 0% to 100%. Data points for Memantine/Donepezil are marked with circles and Placebo/Donepezil with squares.*

FDA Label Image

Container Label 5 mg (00171da8 B6f1 4f4d Afd9 04f7ea35dd04 10)

Memantine Hydrochloride Tablets USP, 5 mg film-coated tablets in a package of 60 tablets. The label shows the NDC number 68180-229-07 and states the product is for oral use. Manufactured for Lupin Pharmaceuticals, Inc., Baltimore, Maryland, and by Lupin Limited, Goa, India. Storage and dispensing instructions are included.*

FDA Label Image

Carton Label 5 mg (00171da8 B6f1 4f4d Afd9 04f7ea35dd04 11)

Packaging label for Memantine Hydrochloride Tablets USP 5 mg film-coated tablets by Lupin Pharmaceuticals, Inc. The label indicates this is a prescription drug with 100 tablets (10 x 10 unit-dose). It includes storage instructions, pharmacist dispensing information, and manufacturer details, with a barcode and the NDC 68180-229-13.*

FDA Label Image

Container Label 10 mg (00171da8 B6f1 4f4d Afd9 04f7ea35dd04 12)

Label for Memantine Hydrochloride Tablets USP 10 mg film-coated tablets, oral dosage form. The packaging contains 60 tablets and is labeled by Lupin Pharmaceuticals, Inc. Manufactured by Lupin Limited in India. The label includes storage instructions and dispensing information for pharmacists.*

FDA Label Image

Carton Label 10 mg (00171da8 B6f1 4f4d Afd9 04f7ea35dd04 13)

Packaging label for Memantine Hydrochloride Tablets USP 10 mg, film-coated oral tablets. The label indicates a package of 100 tablets in 10 unit-dose packs. Manufactured for Lupin Pharmaceuticals, Inc. and by Lupin Limited in India. Storage instructions and pharmacist dispensing information are included.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.